vs

Side-by-side financial comparison of Civeo Corp (CVEO) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.

NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $161.6M, roughly 1.2× Civeo Corp). Civeo Corp runs the higher net margin — -4.0% vs -57.9%, a 53.9% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs 7.1%). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (6.5% CAGR vs -1.4%).

The Civeo Corporation is an American accommodation services multinational corporation. It is a spin-off of Oil States International. It is a public company listed on the New York Stock Exchange.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

CVEO vs NEO — Head-to-Head

Bigger by revenue
NEO
NEO
1.2× larger
NEO
$186.7M
$161.6M
CVEO
Growing faster (revenue YoY)
NEO
NEO
+4.0% gap
NEO
11.1%
7.1%
CVEO
Higher net margin
CVEO
CVEO
53.9% more per $
CVEO
-4.0%
-57.9%
NEO
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
6.5%
-1.4%
CVEO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CVEO
CVEO
NEO
NEO
Revenue
$161.6M
$186.7M
Net Profit
$-6.5M
$-108.0M
Gross Margin
22.7%
43.3%
Operating Margin
-0.1%
46.9%
Net Margin
-4.0%
-57.9%
Revenue YoY
7.1%
11.1%
Net Profit YoY
58.1%
42.0%
EPS (diluted)
$-0.58
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVEO
CVEO
NEO
NEO
Q1 26
$186.7M
Q4 25
$161.6M
$190.2M
Q3 25
$170.5M
$187.8M
Q2 25
$162.7M
$181.3M
Q1 25
$144.0M
$168.0M
Q4 24
$151.0M
$172.0M
Q3 24
$176.3M
$167.8M
Q2 24
$188.7M
$164.5M
Net Profit
CVEO
CVEO
NEO
NEO
Q1 26
$-108.0M
Q4 25
$-6.5M
Q3 25
$-455.0K
$-27.1M
Q2 25
$-3.3M
$-45.1M
Q1 25
$-9.8M
$-25.9M
Q4 24
$-15.4M
Q3 24
$-5.1M
$-17.7M
Q2 24
$8.2M
$-18.6M
Gross Margin
CVEO
CVEO
NEO
NEO
Q1 26
43.3%
Q4 25
22.7%
43.8%
Q3 25
25.7%
42.8%
Q2 25
25.3%
42.6%
Q1 25
20.4%
43.6%
Q4 24
18.6%
44.9%
Q3 24
21.4%
44.6%
Q2 24
25.4%
44.1%
Operating Margin
CVEO
CVEO
NEO
NEO
Q1 26
46.9%
Q4 25
-0.1%
-7.1%
Q3 25
4.1%
-14.4%
Q2 25
1.7%
-26.3%
Q1 25
-3.8%
-16.6%
Q4 24
-6.7%
-10.7%
Q3 24
0.0%
-12.6%
Q2 24
6.9%
-13.3%
Net Margin
CVEO
CVEO
NEO
NEO
Q1 26
-57.9%
Q4 25
-4.0%
Q3 25
-0.3%
-14.4%
Q2 25
-2.0%
-24.9%
Q1 25
-6.8%
-15.4%
Q4 24
-10.2%
Q3 24
-2.9%
-10.5%
Q2 24
4.4%
-11.3%
EPS (diluted)
CVEO
CVEO
NEO
NEO
Q1 26
$-0.13
Q4 25
$-0.58
Q3 25
$-0.04
Q2 25
$-0.25
Q1 25
$-0.72
Q4 24
$-1.04
Q3 24
$-0.36
Q2 24
$0.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVEO
CVEO
NEO
NEO
Cash + ST InvestmentsLiquidity on hand
$14.4M
$146.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$174.4M
$828.8M
Total Assets
$477.4M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVEO
CVEO
NEO
NEO
Q1 26
$146.1M
Q4 25
$14.4M
$159.6M
Q3 25
$12.0M
$164.1M
Q2 25
$14.6M
$154.7M
Q1 25
$28.4M
$346.2M
Q4 24
$5.2M
$367.0M
Q3 24
$17.9M
$362.0M
Q2 24
$7.4M
$355.1M
Total Debt
CVEO
CVEO
NEO
NEO
Q1 26
Q4 25
$341.9M
Q3 25
Q2 25
Q1 25
Q4 24
$43.3M
$541.1M
Q3 24
Q2 24
Stockholders' Equity
CVEO
CVEO
NEO
NEO
Q1 26
$828.8M
Q4 25
$174.4M
$836.6M
Q3 25
$182.5M
$838.3M
Q2 25
$209.4M
$854.0M
Q1 25
$220.7M
$888.3M
Q4 24
$236.4M
$902.3M
Q3 24
$282.2M
$908.2M
Q2 24
$297.4M
$915.9M
Total Assets
CVEO
CVEO
NEO
NEO
Q1 26
$1.3B
Q4 25
$477.4M
$1.4B
Q3 25
$491.1M
$1.4B
Q2 25
$508.8M
$1.4B
Q1 25
$423.8M
$1.6B
Q4 24
$405.1M
$1.6B
Q3 24
$477.6M
$1.6B
Q2 24
$483.2M
$1.6B
Debt / Equity
CVEO
CVEO
NEO
NEO
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.18×
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVEO
CVEO
NEO
NEO
Operating Cash FlowLast quarter
$19.3M
$-8.1M
Free Cash FlowOCF − Capex
$14.5M
FCF MarginFCF / Revenue
8.9%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVEO
CVEO
NEO
NEO
Q1 26
$-8.1M
Q4 25
$19.3M
$1.3M
Q3 25
$13.8M
$8.9M
Q2 25
$-2.3M
$20.3M
Q1 25
$-8.4M
$-25.3M
Q4 24
$9.5M
$9.8M
Q3 24
$35.7M
$9.2M
Q2 24
$32.4M
$13.9M
Free Cash Flow
CVEO
CVEO
NEO
NEO
Q1 26
Q4 25
$14.5M
$-6.5M
Q3 25
$8.2M
$570.0K
Q2 25
$-6.8M
$14.0M
Q1 25
$-13.7M
$-29.8M
Q4 24
$1.8M
$-1.8M
Q3 24
$28.2M
$-1.6M
Q2 24
$27.0M
$814.0K
FCF Margin
CVEO
CVEO
NEO
NEO
Q1 26
Q4 25
8.9%
-3.4%
Q3 25
4.8%
0.3%
Q2 25
-4.2%
7.7%
Q1 25
-9.5%
-17.8%
Q4 24
1.2%
-1.0%
Q3 24
16.0%
-0.9%
Q2 24
14.3%
0.5%
Capex Intensity
CVEO
CVEO
NEO
NEO
Q1 26
Q4 25
3.0%
4.1%
Q3 25
3.3%
4.4%
Q2 25
2.8%
3.5%
Q1 25
3.7%
2.7%
Q4 24
5.1%
6.7%
Q3 24
4.2%
6.4%
Q2 24
2.8%
8.0%
Cash Conversion
CVEO
CVEO
NEO
NEO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
3.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons